NCT06565247View on ClinicalTrials.gov

Evaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic Validation

PHASE3RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 14, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2031

Conditions
Prostate Cancer
Interventions
DRUG

[18F]PSMA-PET

Pre-surgical imaging using \[18F\]PSMA-PET at Umea University Hospital, 3.5 MBq/kg, i.v. injection.

DEVICE

MRI sequences optimized for prostate cancer examinations

T2-WI, T1-WI, DCE and DWI at Umea University Hospital and at Skåne University Hospital

Trial Locations (2)

Unknown

RECRUITING

Region Skåne, Malmo

RECRUITING

Region Västerbotten, Umeå

All Listed Sponsors
collaborator

Umeå University

OTHER

collaborator

Region Skane

OTHER

collaborator

Lund University

OTHER

lead

Region Västerbotten

OTHER_GOV